Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest

• US 7,642,064 B2
• Filed: 12/20/2004
• Issued: 01/05/2010
• Est. Priority Date: 06/24/2003
• Status: Active Grant

• Current Assignee: Ventana Medical Systems Incorporated (Roche Holding AG)
• Original Assignee: Ventana Medical Systems Incorporated (Roche Holding AG)
• Inventors: Farrell, Michael, Bieniarz, Christopher
• Primary Examiner(s): Lam; Ann Y
• Assistant Examiner(s): Grun; James L
• Application Number:
  US11/015,646
• Publication Number:
  US 20050100976A1
• Time in Patent Office: 1,842 Days
• Field of Search: 435/7.1, 435/7.91, 435/7.94, 435/19, 435/21, 435/40.5, 435/14, 435/188, 436/503, 436/514, 436/518, 436/524, 436/528, 436/164
• US Class Current: 435/7.94
• CPC Class Codes: C07F 9/093 Polyol derivatives esterified at least twice by phosphoric acid groups
• CPC Class Codes: C07F 9/65517 condensed with carbocyclic rings or carbocyclic ring systems
• CPC Class Codes: C07F 9/65522 condensed with carbocyclic rings or carbocyclic ring systems
• CPC Class Codes: C07H 15/20 Carbocyclic rings
• CPC Class Codes: C07H 15/24 Condensed ring systems having three or more rings
• CPC Class Codes: C07H 15/26 Acyclic or carbocyclic radicals, substituted by hetero rings
• CPC Class Codes: G01N 33/581 with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Abstract

The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.

Claims

1. A method of detecting and quantifying an analyte of interest from a biological sample in an enzyme immunoassay (EIA), comprising the steps of:

(a) contacting said biological sample with a primary antibody immobilized on a solid support, such that a primary antibody-analyte complex will form when analyte is present in the biological sample;

(b) contacting said complex formed in step (a) with a secondary antibody conjugated to a label enzyme selected from the group consisting of alkaline phosphatase, acid phosphatase, alpha- and beta-galactosidases, and esterases, such that a primary antibody-analyte-secondary antibody complex will form when analyte is present in the biological sample;

(c) contacting said primary antibody-analyte-secondary antibody complex formed in step (b) with a redox inactive reductive species in the presence of metal ion, wherein said redox inactive reductive species is a substrate for said label enzyme, and wherein said label enzyme converts said redox inactive reductive species to a redox active reductive species that reduces said metal ion such that a metal precipitate will form on the solid support following reduction of said metal ion;

(d) enhancing said metal precipitate; and

(e) detecting and quantifying the analyte in the biological sample by quantifying the metal precipitate formed on the solid support.

2. The method of claim 1, wherein said label enzyme is alkaline phosphatase, and said redox-inactive reductive species is ascorbic acid phosphate.

3. The method of claim 1, wherein said label enzyme is alkaline phosphatase, and said redox-inactive reductive species is a hydroquinone phosphate derivative.

4. The method of claim 3, wherein said redox-inactive reductive species is hydroquinone diphosphate.

5. The method of claim 1, wherein said label enzyme is selected from the group consisting of alkaline phosphatase and acid phosphatase, and said redox-inactive reductive species is selected from the group consisting of hydroquinone mono- and di-phosphates, naphthohydroquinone mono- and di-phosphates, and anthrahydroquinone mono- and di-phosphates.

6. The method of claim 1, wherein said label enzyme is selected from the group consisting of alkaline phosphatase and acid phosphatase, and said redox-inactive reductive species is selected from the group consisting of sesamol phosphate, eugenol phosphate and alpha-tocopherol phosphate.

7. The method of claim 1, wherein said metal ion is selected from the group consisting of silver ion and gold ion.

8. The method of claim 7, wherein said metal ion is silver ion.

9. The method of claim 8, wherein prior to the reduction of silver ion in step (c), the biological sample is pretreated with gold ion.

10. The method of claim 1, wherein said EIA is an enzyme-linked immunosorbent assay (ELISA).

11. The method of claim 1, wherein said label enzyme is alkaline phosphatase.

12. The method of claim 1, wherein said label enzyme is acid phosphatase.

13. The method of claim 1, wherein said label enzyme is alpha- or beta-galactosidase.

14. The method of claim 1, wherein said label enzyme is an esterase.